Abstract:Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound 27h (designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2 = 4.98 h). Significantly, oral administration of compound 27h achieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound 27h may serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00763?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00763</a>.Virtual screening results from the molecular docking; compounds identified as hits against RORγ from virtual screening; overlaid complex structures of compound XY101 and compound 27h; overlaid structures of compounds 27g and 27h; western blot analysis of the AR and AR variants levels in 22Rv1 cells treated with compound 27h; metabolic stability of 25c, 25p, 27g, and 27h in human and rat liver microsomes; 1H and 13C NMR spectra of the synthesized compounds; and HPLC traces of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_001.pdf">PDF</a>)Molecular formula strings for compounds with associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_002.csv">CSV</a>)Database files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery and pharmacological characterization of 1,2,3,4-tetrahydroquinoline derivatives as RORγ inverse agonists against prostate cancer

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.

Discovery of Pyridine Tetrahydroisoquinoline Thiohydantoin Derivatives with Low Blood-Brain Barrier Penetration As the Androgen Receptor Antagonists.

Exploring the Tetrahydroisoquinoline Thiohydantoin Scaffold Blockade the Androgen Receptor As Potent Anti-Prostate Cancer Agents.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist

Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells

Discovery of Thiohydantoin Based Antagonists of Androgen Receptor with Efficient Degradation for the Treatment of Prostate Cancer

Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.

Discovery of Novel Thiohydantoin Derivatives As Full Antagonists and Efficient Degraders of Androgen Receptor

Discovery of Novel Flavonoid-Based CDK9 Degraders for Prostate Cancer Treatment Via a PROTAC Strategy.

Discovery of novel 5-methyl-1H-pyrazole derivatives as potential anti-prostate cancer agents: design, synthesis, molecular modeling and biological evaluation.

Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.

Discovery of dolutegravir-1,2,3-triazole derivatives against prostate cancer via inducing DNA damage

Discovery of Tetrahydroquinolines and Benzomorpholines As Novel Potent Ror Gamma T Agonists

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells

A Combined Quantitative Structure-Activity Relationship Research of Quinolinone Derivatives As Androgen Receptor Antagonists.

Discovery and Characterization of 1H-1,2,3-triazole Derivatives As Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.

Identification of the gossypol derivatives as androgen receptor inhibitor